Data from MHRA (Medicines and Healthcare products Regulatory Agency, UK) - Curated by EPG Health - Last updated 01 March 2018


DDAVP Tablets are indicated for the treatment of vasopressin-sensitive cranial diabetes insipidus or in the treatment of post-hypophysectomy polyuria/polydipsia.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Type 2 Diabetes

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.



Learn about the complex factors influencing development of obesity.

+ 4 more

Load more

Related Content

More information

Category Value
Authorisation number 0.1mg: PL 03194/0040 - 0.2mg: PL 03194/0041
Orphan designation No
Date First Approved 12-01-2003
Type Medicinal product subject to medical prescription
Marketing authorisation holder Ferring Pharmaceuticals Ltd